Purpose: The purpose of the study was to evaluate the efficacy and safety of the PAUL glaucoma implant (PGI) in refractory glaucoma patients, during the early postoperative period.
Methods: We conducted a retrospective, cohort study of patients that had received a PGI between February 2022 and December 2023. An intraluminal polypropylene suture was placed to prevent early hypotony in all cases. Demographics, intraocular pressure (IOP), and medication variation were evaluated for up to 6 months. The success rate was stratified into <18 mmHg and 30% from baseline or <15 mmHg and 40% IOP reduction. The safety outcomes were also analyzed.
Results: Sixteen eyes from 16 patients were included in the analysis. Fifteen of them had had a previous surgical glaucoma procedure. At 6 months, IOP decreased from 26.6 (±6.2) to 15.3 (±4.6) mmHg, with fewer glaucoma medications, from a median (interquartile range) of 3 (2-3) - 1.5 (0-2) ( < 0.005). Twelve (75%) and seven (43.8%) eyes met the qualified and complete success definition for the first category, and eight (50%) and four (25%) met the second criterion. One case with self-limiting choroidal detachments, but >6 mmHg IOP was found in our cohort.
Conclusion: The PGI seems to be safe and effective from the early postoperative period. The IOP reduction rate could make it suitable for patients with refractory moderate-to-advanced glaucoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811398 | PMC |
| http://dx.doi.org/10.4103/sjopt.sjopt_164_24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reply.
Ophthalmol Glaucoma
March 2025
Center for Community Outreach and Policy, Department of Ophthalmology, Stein and Doheny Eye Institutes, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address:
Reply.
Ophthalmol Glaucoma
March 2025
Center for Community Outreach and Policy, Department of Ophthalmology, Stein and Doheny Eye Institutes, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address:
Successful management with Paul Glaucoma Drainage Implant after complicated bleb needling with uveal prolapse into the bleb ten years after trabeculectomy.
BMC Ophthalmol
February 2025
Department of Ophthalmology, University Eye Hospital, Hannover Medical School, Hannover, Germany.
Background: Fibrosis is the primary cause of failure following glaucoma surgery. Wound healing modulation with 5-fluorouracil and mitomycin-C is routinely employed to reduce ocular fibrosis and improve surgical success rates; however, it also increases the risk of postoperative complications.
Case Presentation: A 59-year-old patient with a family history of glaucoma presented a decade after bilateral trabeculectomy with an intraocular pressure (IOP) of 30 mmHg in the right eye and 42 mmHg in the left eye.
Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON).
Drugs
February 2025
Allergan, an Abbvie company, Irvine, CA, USA.
Background: Bimatoprost implant 10 µg is an intracameral, biodegradable implant that slowly releases bimatoprost to lower intraocular pressure (IOP). This study was designed to evaluate safety and the duration of the IOP-lowering effect after single and as-needed repeat administration of the bimatoprost implant in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).
Patients And Methods: This study is an interim analysis of an ongoing, prospective, open-label, multicenter study in patients with OAG or OHT who are inadequately managed with topical IOP-lowering medication for reasons other than efficacy.
Paul versus Baerveldt 350 glaucoma drainage implants: One-year comparative analysis.
Indian J Ophthalmol
March 2025
VERTE_ICO Ophthalmology, Via Augusta 61; 08006 Barcelona, Spain.
Purpose: This study aimed to evaluate and compare the effectiveness and safety of Paul glaucoma implant (PGI) and Baerveldt 350 glaucoma implant (BGI) over a 1-year follow-up period.
Methods: This retrospective study was conducted in a private clinic. It compared 27 patients consecutively treated with the PGI to a historical cohort of 29 eyes that received the BGI prior to the introduction of the PGI between 2018 and 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!